CapsoVision (CV) Cash from Operations (2024 - 2025)

CapsoVision (CV) reported Cash from Operations of 7686000.0 for Q4 2025, down 42.36% on a YoY basis from 13334419.67 in Q4 2024, and down 35.65% sequentially from 5666000.0 in Q3 2025.

CapsoVision (CV) Cash from Operations (2024 - 2025) Analysis & Trends

CapsoVision (CV) has 2 years of Cash from Operations data on file, last reported at 7686000.0 in Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 42.36% year-over-year to 7686000.0; the trailing twelve-month figure through Dec 2025 stood at 25807000.0 (changed N/A YoY), and the FY2025 full-year result was 22864000.0, down 13.8% from the prior year.
  • Cash from Operations declined to 7686000.0 in Q4 2025, from 5666000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 5399000.0 in Q4 2024 to a low of 7686000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 1.32 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 581.00 Mn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 2.57 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 348.00 Mn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn 43.80 Mn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 525.60 Mn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 220.10 Mn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 290.00 Mn
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 CapsoVision 162.07 Mn 151.95 Mn 1.95 Mn -7.69 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -7.69 Mn
Dec 31, 2025 -7.69 Mn
Sep 30, 2025 -5.67 Mn
Sep 30, 2025 -5.67 Mn
Dec 31, 2024 -5.40 Mn
Dec 31, 2024 -5.40 Mn
Sep 30, 2024 -7.06 Mn
Sep 30, 2024 -7.06 Mn